Multivariate Cox proportional hazard analysis of PFS in the ARCTIC-ADMIRE trials
| Significant variables . | HR (95%CI) . | P . |
|---|---|---|
| Analysis I | ||
| Epigenetic subgroups | ||
| n-CLL | — | — |
| i-CLL | 0.59 (0.39-0.90) | .014 |
| m-CLL | 0.23 (0.14-0.40) | <.001 |
| del(11q) (present vs absent) | 1.70 (1.15-2.52) | .008 |
| del(17p) (present vs absent) | 6.03 (3.31-10.97) | <.001 |
| Analysis II | ||
| Epigenetic subgroups | ||
| n-CLL | — | — |
| i-CLL | 0.89 (0.50-1.59) | ns |
| m-CLL | 0.25 (0.10-0.57) | .002 |
| del(11q) (present vs absent) | 2.36 (1.36-4.11) | .002 |
| del(17p) (present vs absent) | 3.87 (1.66, 9.01) | .002 |
| TP53 mutation (present vs absent) | 3.28 (1.54-7.00) | .002 |
| Significant variables . | HR (95%CI) . | P . |
|---|---|---|
| Analysis I | ||
| Epigenetic subgroups | ||
| n-CLL | — | — |
| i-CLL | 0.59 (0.39-0.90) | .014 |
| m-CLL | 0.23 (0.14-0.40) | <.001 |
| del(11q) (present vs absent) | 1.70 (1.15-2.52) | .008 |
| del(17p) (present vs absent) | 6.03 (3.31-10.97) | <.001 |
| Analysis II | ||
| Epigenetic subgroups | ||
| n-CLL | — | — |
| i-CLL | 0.89 (0.50-1.59) | ns |
| m-CLL | 0.25 (0.10-0.57) | .002 |
| del(11q) (present vs absent) | 2.36 (1.36-4.11) | .002 |
| del(17p) (present vs absent) | 3.87 (1.66, 9.01) | .002 |
| TP53 mutation (present vs absent) | 3.28 (1.54-7.00) | .002 |
Two multivariable models were built (Analysis I and II) for the progression-free survival (PFS) of patients from ARCTIC/ADMIRE, using a step-wise backward elimination process. The 2 models shown here include all significant predictors remaining at the end of the backward elimination analyses. Analysis I: Variables included at the start of the backward elimination process were epigenetic subgroups, age, sex, treatment, stage, IGHV mutational status, del(11q), and del(17p). The final model was based on 236 patients and 132 progressions. Analysis II: The variables included in the model initially were epigenetic subgroups, age, sex, treatment, stage, IGHV mutational status, del(11q), del(17p), TP53 mutation, combined NOTCH1 coding and 3′UTR mutations and SF3B1 mutations. The final model was based on 125 patients and 80 events. Estimates (95% CI) and P values for IGHV-mutation status (IGHV-M v -U) were HR, 0.58 (95% CI, 0.31-1.07; P = .082; Analysis I) and HR, 0.56 (95% CI, 0.23-1.34; P = .195; Analysis II).